Loading…
Based on limited metadata, the FDA issued a Warning Letter to GPT Pharmaceuticals Private Ltd on December 17, 2019, regarding drug products. Without access to the full letter text or specific subject line details, the exact nature of the violations cannot be determined from the available information. The letter falls under FDA's drug product regulatory authority, though the specific issuing office is not identified in the metadata provided. To understand the precise compliance issues cited, review of the complete Warning Letter would be necessary.